Auto-generated event page

InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China

InnoCare’s next-generation TRK inhibitor Zurletrectinib receives priority review for the treatment of pediatric patients with solid tumors in China.

Score 41 low confidence 1 source posts Updated Mar 2, 2026, 2:10 AM UTC

Track This Event Open Event in App More Signal Pages

Cluster sources

Newest source rows first.

InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China

GlobeNewswire Public Companies • Mar 2, 2026, 2:03 AM UTC

Entity focus

Direct link to post

https://pushme.site/signals/169627-innocare-s-next-generation-trki-zurletrectinib-receives-priority-review-?utm_source=signal-169627&utm_medium=social&utm_campaign=signal-pages&utm_content=hero

Quick distribution loop

Step 1

Post this live link in threads where users ask how to monitor this event.

Step 2

Point readers to "Track This Event" for immediate conversion into an alert.

Step 3

Reuse entity keywords from this page for targeted follow-up replies.

Back to signal pages Open query hub